Engineered immune cells take aim at childhood cancers in early trial
NCT ID NCT04483778
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B7H3 found on many solid tumors. The main goals are to check safety, find the best dose, and see if the cells can persist in the body.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive antibody light up hidden tumors?
- Can new drug cocktails reawaken the immune system against melanoma?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new immune drug outsmart Hard-to-Treat tumors?